Cashu
GT Biopharma Advances Immuno-Oncology with IND Application for GTB-5550 Targeting Solid Tumors
2 months ago
Stocks
Health Care
gtbp
GT Biopharma
NASDAQ: GTBP
0.00 (+0.51%)
0.4164
USD
At close at Mar 31, 20:41 UTC
Overview
Loading chart...
Key Stats
Market Cap
4.34M
Dividend Yield
0.00%
P/E Ratio
-0.08
EPS
-7.00
Revenue
-
Avg. Volume
557.14K
About
What does GTBP do?
GT Biopharma, a clinical-stage biopharmaceutical company based in Brisbane, California, focuses on immuno-oncology products using its TriKE NK cell engager platform, with its first candidate, GTB-3550, targeting cancer and HIV. Founded in 2013, the company employs two full-time staff and aims to enhance natural killer cell activity against diseases.
Join our newsletter to keep up to date with us!
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.